PIK3CA Somatic Mutations Are Associated With Lymph Node Metastasis in Endometrial Cancer
Abstract
To investigate the expression levels and mutation status of phosphatidylinositol-4, 5-bisphosphate3-kinase catalytic subunit alpha (PIK3CA) in endometrial cancer (EC) and evaluate its association with lymph node metastasis in EC.
Methods
We retrosepctively collected and analyzed EC genetic mutation testing data submitted to the Molecular Detection Center, The First Affiliated Hospital of Chongqing Medical University between July 2020 and June 2022. The mutation rate of PIK3CA gene was calculated based on the sequencing results of EC patients, and the correlation between PIK3CA mutations and clinical pathological parameters, as well as protein expression consistency, was analyzed accordingly.
Results
A total of 97 EC patients were enrolled in this study, and PIK3CA mutations were identified in approximately 48.5% (47 out of 97 cases). The rate of lymph node metastasis in patients with PIK3CA mutations was higher than that in patients with wild-type PIK3CA (21.3% vs. 6.0%, P = 0.027). Findings from univariate and multivariate logistic analyses indicated that histological subtype Ⅱ (odds ratio [OR] = 5.51; 95% CI, 1.08-28.06; P = 0.040), positive result for lymphovascular space invasion (LVSI) (OR = 7.96; 95% CI, 1.37-46.44; P = 0.021), and PIK3CA mutation (OR = 8.58; 95% CI, 1.51-48.84; P = 0.015) were independent risk factors for lymph node metastasis in EC. In addition, the receiver-operating characteristic (ROC) curves demonstrated that the combined use of clinicopathological parameters and PIK3CA mutations could more accurately predict lymph node metastasis in EC, with an area under the curve of 0.824 (95% CI, 0.678-0.970). It is noteworthy that there was a high consistency between PIK3CA mutations and its protein expression, and EC patients with positive expression of PIK3CA protein had a higher rate of lymph node metastasis (53.8% vs. 9.1%, P = 0.078).
Conclusion
PIK3CA somatic mutations are strongly correlated with lymph node metastasis in EC.
Keywords: Endometrial carcinoma, PIK3CA, Genetic testing, TCGA molecular subtypes
Full Text:
PDFReferences
SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021. CA Cancer J Clin, 2021, 71(1): 7-33. doi: 10.3322/caac.21654.
ZHENG Y, JIANG P, TU Y, et al. Incidence, risk factors, and a prognostic nomogram for distant metastasis in endometrial cancer: a SEER-based study. Int J Gynaecol Obstet, 2024, 165(2): 655-665. doi: 10.1002/ijgo.15264.
BOGANI G, Di DONATO V, PAPADIA A, et al. Evaluating long-term outcomes of three approaches to retroperitoneal staging in endometrial cancer. Gynecol Oncol, 2022, 166(2): 277-283. doi: 10.1016/j.ygyno.2022.06.007.
PETOUSIS S, CHRISTIDIS P, MARGIOULA-SIARKOU C, et al. Combined pelvic and para-aortic is superior to only pelvic lymphadenectomy in intermediate and high-risk endometrial cancer: a systematic review and meta-analysis. Arch Gynecol Obstet, 2020, 302(1): 249-263. doi: 10.1007/s00404-020-05587-2.
SUCHETHA S, REMA P, VIKRAM S, et al. Role of lymphadenectomy and its impact on survival in endometrial carcinoma - an institutional experience. Gulf J Oncolog, 2015, 1(17): 30-33.
BANZ-JANSEN C, HELWEG L P, KALTSCHMIDT B. Endometrial cancer stem cells: Where do we stand and where should we go? Int J Mol Sci, 2022, 23(6): 3412. doi: 10.3390/ijms23063412.
LIU Y, LIU X Y, YAN S M, et al. Clinical application of next-generation sequencing in molecular typing of endometrial cancer. Journal of Sun Yat-Sen University (Medical Sciences), 2023, 44(2): 217-223. doi: 10. 13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0205.
DING Q, ZHU W, DIAO Y, et al. Elucidation of the mechanism of action of ginseng against acute lung injury/acute respiratory distress syndrome by a network pharmacology-based strategy. Front Pharmacol, 2020, 11: 611794. doi: 10.3389/fphar.2020.611794.
LIU J, HAN X, ZHANG T, et al. Reactive oxygen species (ROS) scavenging biomaterials for anti-inflammatory diseases: from mechanism to therapy. J Hematol Oncol, 2023, 16(1): 116. doi: 10.1186/s13045-023-01512-7.
FANG H, YANG Z, YANG L. Protective effect of Houttuynia cordata extract on propofol-induced injury of rat hippocampal neurons by regulating PI3K/Akt and Toll-like receptor 4/NF-κB signaling pathway. Neuroreport, 2021, 32(7): 577-582. doi: 10.1097/wnr.0000000000001627.
COBLEIGH M A, LAYNG K V, MAUER E, et al. Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers. Breast Cancer Res Treat, 2024, 204(2): 407-414. doi: 10.1007/s10549-023-07196-4.
THARIN Z, RICHARD C, DERANGÈRE V, et al. PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy. Sci Rep, 2023, 13(1): 4467. doi: 10.1038/s41598-023-31593-w.
ZHANG J, ZHU J, LENG J, et al. New advances in the study of PIK3CA-related overgrowth spectrum. Journal of Chongqing Medical University, 2023, 48(5): 512-515. doi: 10.13406/j.cnki.cyxb.003238.
BEREK J S, MATIAS-GUIU X, CREUTZBERG C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet, 2023, 162(2): 383-394. doi: 10.1002/ijgo.14923.
ZHENG Y, SHEN Q, YANG F, et al. A nomogram model to predict recurrence of early-onset endometrial cancer after resection based on clinical parameters and immunohistochemical markers: a multi-institutional study. Front Oncol, 2024, 14: 1442489. doi: 10.3389/fonc. 2024.1442489.
OAKNIN A, BOSSE T J, CREUTZBERG C L, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol, 2022, 33(9): 860-877. doi: 10.1016/j.annonc.2022.05.009.
MOSELE F, STEFANOVSKA B, LUSQUE A, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol, 2020, 31(3): 377-386. doi: 10.1016/j.annonc.2019.11.006.
KIM J W, LIM A R, YOU J Y, et al. PIK3CA mutation is associated with poor response to HER2-targeted therapy in breast cancer patients. Cancer Res Treat, 2023, 55(2): 531-541. doi: 10.4143/crt.2022.221.
CATHRYN R H, KUMAR S U, R G, et al. An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer. J Cell Biochem, 2023, 124(2): 188-204. doi: 10.1002/jcb.30354.
PETERS E E M, LEÓN-CASTILLO A, SMIT V, et al. Defining substantial lymphovascular space invasion in endometrial cancer. Int J Gynecol Pathol, 2022, 41(3): 220-226. doi: 10.1097/pgp.0000000000000806.
SUN Y, WANG Y, CHENG X, et al. Risk factors for pelvic and para-aortic lymph node metastasis in non-endometrioid endometrial cancer. Eur J Surg Oncol, 2024, 50(4): 108260. doi: 10.1016/j.ejso.2024.108260.
ANDRÉ F, CIRUELOS E, RUBOVSZKY G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med, 2019, 380(20): 1929-1940. doi: 10.1056/NEJMoa1813904.
AVERDUNK L, STICHT H, SUROWY H, et al. The recurrent missense mutation p. (Arg367Trp) in YARS1 causes a distinct neurodevelopmental phenotype. J Mol Med (Berl), 2021, 99(12): 1755-1768. doi: 10.1007/s00109-021-02124-9.
DRAAISMA K, WIJNENGA M M, WEENINK B, et al. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. Acta Neuropathol Commun, 2015, 3: 88. doi: 10.1186/s40478-015-0265-4.
LI H, CHEN S, LI H, et al. Association between PIK3CA alteration and prognosis of gastric cancer patients: a meta-analysis. Oncotarget, 2018, 9(7): 7651-7659. doi: 10.18632/oncotarget.23871.
Refbacks
- There are currently no refbacks.
